Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 20;18(4):3014–3024. doi: 10.3892/etm.2019.7930

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Skálová et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Representative images of changes in the expression of claudins in invasive breast carcinoma no special type following neoadjuvant chemotherapy. (A) Punctate membranous positivity of claudin-1 in a core needle biopsy prior to therapy. Magnification, ×200. (B) Strong and continuous membrane staining of claudin-1 in the residual cancer from the same patient. Magnification, ×600. (C) Punctate-to-continuous membranous positivity of claudin-1 in a core needle biopsy prior to therapy. Magnification, ×200. (D) Similar staining pattern of claudin-1 in the residual cancer from the same patient. Continuous and intense positivity was observed in ductal carcinoma in situ (black arrow) and in the small residual non-tumour duct (white arrow). Magnification, ×200. (E) Strong and continuous membranous staining of claudin-3 in a core needle biopsy prior to therapy. Magnification, ×600. (F) Faint claudin-3 staining in the residual cancer from the same patient. Magnification, ×600. (G) Moderate membranous positivity of claudin-4 in a majority of the tumour cells in a core needle biopsy before therapy (retraction artefacts). Magnification, ×600. (H) Similar staining pattern of claudin-4 (comparing membranous positivity only) in the residual cancer from the same patient. Magnification, ×200.